All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Tovorafenib Elicits Responses in Recurrent or Progressive Pediatric Low-Grade Glioma

January 9th 2023

Tovorafenib monotherapy generated responses in patients with recurrent or progressive pediatric low-grade glioma.

Seismic Change Occurs in Small Bites

January 9th 2023

The Dobbs v Jackson Women’s Health Organization decision, a landmark decision of the US Supreme Court in which the court held that the Constitution of the United States does not confer a right to abortion, will most likely affect your practice.

Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer

January 9th 2023

Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC

January 8th 2023

Neoadjuvant treatment with SHR-1701 with or without chemotherapy followed by surgery or radiotherapy induced responses in more than half of patients with stage III unresectable non–small cell lung cancer and increased resectability in those assigned to definitive surgery.

Pexidartinib With Surgery Proves Potential Benefit for Patients With Tenosynovial Giant Cell Tumors

January 7th 2023

R. Lor Randall, MD, FACS, discusses the outcomes of combining surgery and pexidartinib in patients with tenosynovial giant cell tumors, what investigators still need to learn about sequencing the CSF1R inhibitor around surgery, and what the combination approach could mean for patients with TGCT.

Developmental FGFR Inhibitors Are Active in FGFR+ Cholangiocarcinoma and Urothelial Carcinoma

January 6th 2023

Mitesh J. Borad, MD, explains how FGFR alterations influence treatment strategies in cholangiocarcinoma and urothelial cancer, discusses the FGFR resistance mechanisms that are prompting further research in this area, and highlights the rationale for the KN-4802 trial.

Fox Chase Cancer Center President and CEO Dr. Robert Uzzo Presents Rhoads Oration for Philadelphia Academy of Surgery

January 6th 2023

Joining a list of over 100 previous orators, Robert Uzzo, MD, MBA, FACS, president and CEO of Fox Chase Cancer Center, delivered the Rhoads Oration for the Philadelphia Academy of Surgery this month at The College of Physicians of Philadelphia.

Abequolixron Plus Docetaxel Elicits Responses in Relapsed/Refractory Lung Cancer

January 6th 2023

The addition of abequolixron to docetaxel generated responses in patients with relapsed/refractory non–small cell lung cancer or small cell lung cancer.

Japan Approves Acalabrutinib for Treatment-Naïve CLL

January 6th 2023

Japan’s Ministry of Health, Labor, and Welfare has approved acalabrutinib for the treatment of previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Priority Review to Glofitamab for Relapsed/Refractory LBCL

January 6th 2023

The FDA has accepted a biologics license application for glofitamab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Japan Approves Durvalumab/Tremelimumab Combo for HCC and Advanced NSCLC

January 6th 2023

Japan has approved durvalumab monotherapy and durvalumab plus tremelimumab for unresectable hepatocellular carcinoma, durvalumab plus tremelimumab and chemotherapy for unresectable, advanced, or recurrent non–small cell lung cancer, and durvalumab plus chemotherapy for curatively unresectable biliary tract cancer.

Breast Cancer Advances in 2022 Showcase a Shifting Landscape

January 6th 2023

Joseph A. Sparano, MD, highlights practice-changing clinical trials, novel therapies, the evolving treatment landscape, and unmet needs in the field of breast cancer.

Obe-cel Provides Favorable Safety Profile, Expands Potential Treatment Options in B-ALL

January 6th 2023

Paul J. Shaughnessy, MD, discusses the unique properties of obecabtagene autoleucel in B-cell acute lymphoblastic leukemia and how findings from the FELIX trial support further research into the benefits of CAR T-cell therapy in patients with hematologic malignancies.

FDA Grants Fast Track Status to BT8009 for Previously Treated Locally Advanced or Metastatic Urothelial Cancer

January 5th 2023

The FDA has granted a fast track designation to BT8009 for use as a monotherapy in adult patients with previously treated locally advanced or metastatic urothelial cancer.

Mitazalimab Plus mFOLFIRINOX Delivers High ORR in Previously Untreated Metastatic Pancreatic Cancer

January 5th 2023

Adding mitazalimab to mFOLFIRINOX led to a 52% objective response rate as frontline therapy in 23 patients with metastatic pancreatic cancer.

Trilaciclib Plus Chemotherapy and Avelumab Maintenance Generates Comparable ORR in Advanced/Metastatic Urothelial Carcinoma

January 5th 2023

Adding the CDK4/6 inhibitor trilaciclib to platinum-based chemotherapy and avelumab maintenance produced an overall response rate comparable to chemotherapy and maintenance avelumab alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

TAVT-45 Granules Show Equivalence to Abiraterone Tablets in Metastatic Prostate Cancer

January 5th 2023

Abiraterone acetate granules for oral suspension demonstrated therapeutic equivalence and comparable safety to the original formulation of abiraterone acetate in patients with metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for Entrectinib

January 5th 2023

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for use with the selective TKI entrectinib. The assay identifies patients with ROS1-positive NSCLC or NTRK fusion–positive solid tumors who do not have a tissue sample available and who may be appropriate for entrectinib treatment.

Discrete Data Are Key to Realizing Electronic Health Records’ Full Potential

January 5th 2023

Electronic health record systems’ design, usability, and interoperability issues can hinder integration and use.

TTFields Plus SOC Meets Primary End Point in Stage IV NSCLC After Failure of Platinum-Based Chemotherapy

January 5th 2023

Tumor treating fields plus standard-of-care therapies led to a statistically significant and clinically meaningful improvement in overall survival vs SOC alone in patients with stage IV NSCLC who progressed while on or after platinum chemotherapy, meeting the primary end point of the LUNAR trial.